University of Pennsylvania

University of Texas System

Advaxis, Inc.

Vetigenics, Inc.

Nicola Mason

Yvonne Paterson

Daniel J Powell

Mohammed Kazim Panjwani

Jenessa Smith

Donald L Siegel

Paulo Cesar Maciag

Matthew Seavey

Anu Wallecha

Vafa Shahabi

Laurence Jn Cooper

Colleen M O'Connor

Nicholas Chester

The present invention relates to compositions and methods for the treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor. One aspect includes a modified canine T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity in canine.

Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor

The present invention relates to canine antibodies, binding polypeptides, and scFvs specific for canine cytotoxic T lymphocyte associated protein 4 (CTLA-4).

Canine monoclonal antibodies against canine cytotoxic T lymphocyte associated protein 4 (CTLA-4)

This invention provides methods for inducing an immune response against a Her-2/neu antigen-expressing tumor and for treating the same and vaccinating against the same in human and canine subjects using a combination of radiation therapy and a recombinant attenuatedstrain vaccine.

Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers

This invention provides compositions and methods for treating and vaccinating against an Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a non-human animal.

Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors

The invention is generally directed to antibody variable domains or antibodies, libraries of antibody variable domains or antibodies, methods of making said antibodies and libraries, and methods of treatment comprising administering the generated antibody variable domains or antibodies. Specifically, the invention is directed to novel primer nucleotide sequences that are used to amplify all rearranged sequences of canine variable heavy (VH) and variable light (VL) immunoglobulin chains that have been used in naturally occurring antibody responses. These novel sequences contain canine framework regions and complementarity determining regions which may be used to canine-ize antibodies. Further, these sequences are useful for the identification and targeting of viral and bacterial pathogens, and tumor-associated antigens.

Single chain fragment variable antibody libraries and uses thereof

Growing community of inventors

Philadelphia, PA, United States of America

Nicola Mason